BRCA1/2-Mutated Breast Cancer in Select EU Markets: Incidence, Treatable Populations, and Potential Market Size for Parp Inhibitors

Value in Health - United Kingdom
doi 10.1016/j.jval.2017.08.397
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV


Related search